Valeant announces 10% Q4 revenue increase

Valeant has announced its 2014 fourth-quarter financial results, which included a total revenue of $2.3 billion, marking a 10% increase from the previous year.

The increase was seen despite a negative foreign exchange impact of $113 million, according to a company press release.

For its 2014 full-year results, the company reported a total revenue of $8.3 billion, or a 43% increase from the previous year, according to the release.

Total same store sales had organic growth of 16% for the fourth quarter and 13% for 2014 full-year results, whereas Bausch + Lomb organic growth was 8% for the fourth quarter and 11% for 2014, according to the release.

Valeant also announced it expects to close its acquisition of Dendreon on Feb. 23, which will include gaining world-wide rights to Dendreon’s Provenge (sipueleucel-T), a cell-based immunotherapy for treating prostate cancer, and other assets.

Reference: www.valeant.com.